Biosimilar Pipeline Report: Winter 2022/2023

In this report, IPD Analytics provides an outlook for potential approvals and launches across the biosimilar landscape over the 2023–2026 horizon.

Our team of pharmacists, PhD scientists, and intellectual property attorneys continuously monitor and update our comprehensive pipeline intelligence database.

Subscribers use this report as a companion to our online Clinical Development Tracker within our Payer & Provider Insights platform, which provides up-to-date clinical pipeline information on thousands of products across various disease classes and therapeutic areas. In tandem, these reports deliver insight into trending classes that will affect the competitive landscape and your drug spend.